C. diff drug linked to hypersensitivity reactions, FDA says

11/11/2013 | Healio (free registration)

The FDA said it received data on 11 post-approval cases of hypersensitivity linked to the drug fidaxomicin, which is prescribed to treat Clostridium difficile infection. The agency said hypersensitivity symptoms were seen from one hour to seven days after the drug was taken and have led to changes in the drug's labeling to warn of the potential reaction.

View Full Article in:

Healio (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA